Amphion Innovations plc

Polarean Update

London and New York, 23 August 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, notes that its partner company Polarean Imaging plc (“Polarean”) has announced that the first patient has been enrolled in its Phase III FDA clinical trial which aims to demonstrate non-inferiority of the Company's drug-device combination, using hyperpolarised 129-Xenon (129Xe) gas MRI, against an approved comparator.

This news means that Polarean is now in the process of its Phase III clinical trial. Polarean is listed on the AIM market of the London Stock Exchange under the ticker POLX.

Amphion currently holds c. 17 million shares, equivalent to 21.7% of the enlarged Share Capital of Polarean.


For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Emma Earl / Ryan McCarthy (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker)
David Hignell (Corporate Finance)
Vadim Alexandre (Corporate Broking)
+44 (0)20 3861 6600

Walbrook PR
Anna Dunphy / Paul McManus
+44 (0)20 7933 8780

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.

Top